We describe procedures for intracellular expression of scFv in eukaryotic cells.
direct interference, or by diverting it from its normal intracellular location (1). In addition, by adding to the scFv a targeting signal, such as a nuclear localization signal (NLS) or a retention signal for the endoplasmic reticulum (ER), expression of the scFv can be restricted to a specific location within the cell.
One of the main problems associated with intrabodies is that most scFvs are not able to fold under the reducing conditions that pertain in the cell cytosol and nucleus. This is due to the limited stability of scFvs after the two conserved disulfide bonds are reduced. The main consequence is the formation of insoluble aggregates, rendering antibodies non-functional ( Fig. 1) . However, even when aggregated, some intrabodies may retain their binding affinity and can sequester the targeted antigen, preventing it to reach its physiological localization and therefore inhibiting its function (2-3). Even if the intrabody is expressed as soluble protein in the cell cytoplasm, its inhibitory potential may be limited by a low expression level and a limited half-life. This has promoted the development of stable frameworks (4) on which scFvs that fold correctly and in sufficient amount to be active as intracellular antibodies can be constructed.
In order to obtain efficient intrabodies, a panel of antibodies against an antigen must be first isolated. This step can be accomplished by different techniques, including phage display, ribosome display, yeast two-hybrid system, or even classical hybridoma technology.
Then, the selected antibodies must be tested in vivo for their correct expression and ability to inhibit their target. Expressing scFvs that have been selected from an optimized library will greatly increase the success rate of this experiment (5-8).
In this chapter, we describe procedures for intracellular expression of scFv in eukaryotic cells. We also give details for the subcloning of a selected scFv sequence into a mammalian expression vector, the transient transfection of Hela cell line and the monitoring of intrabody expression by immunofluorescence staining and FACS analysis. 
Methods
The following protocol assumes that a scFv clone of interest has been first isolated from a library constructed in a pCANTAB or pHEN derived phagemid vector (8). 2. Digest also 1 µg of recipient plasmid pCMV/myc/cyto with the same enzymes (see
Note 5).
3. Purify the 750 bp scFv fragment and recipient plasmid on an agarose gel using a commercial DNA purification kit. 
Cell culture and Transient Transfection of Hela cells (see Note 8)
Human cervix carcinoma Hela cells are grown in DMEM supplemented with 10% heat inactivated FCS at 37 °C in a 5% CO 2 humidified atmosphere. Cells should be seeded 24 h before transfection. 
Gradually rehydrate the cells by adding PBS in aliquot of about 500 µl (see Note 13).
Finally wash cells once in PBS. The expressed scFv will be tagged at its C-terminus with the c-myc epitope recognized by mAb 9E10 (see Note 14). Alternative vector with the stronger EF-1α
promoter is also available from Invitrogen (#V89020).
2. To target your recombinant scFv to a specific intracellular location in mammalian cells (nucleus, mitochondria, endoplasmic reticulum), vectors containing a targeting signal are also available from Invitrogen (for example pCMV/myc/nuc, pCMV/myc/mit, pCMV/myc/ER vectors).
3. The NcoI site contains the ATG initiation codon. If you wish to also include the tag, make sure to clone the c-myc epitope in frame at the NotI site. This is the case if your scFv is cloned from pCANTAB or pHEN vectors.
4. The scFv sequence can also be obtained by PCR using appropriate oligonucleotides.
Design primers to introduce a NcoI site at the 5' end and a NotI site at the 3' end of the gene in the correct frame (see Note 3). Digest PCR product, and purify on silica-based columns. 
